3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Glioblastoma
41
Glioma
18
Brain Neoplasms
14
Astrocytoma
11
Neuroblastoma
10
Gliosarcoma
10
Neoplasms
8
Sarcoma, Ewing
7
Rhabdomyosarcoma
6
Recurrence
5
Oligodendroglioma
5
Sarcoma
4
Medulloblastoma
4
Neoplasm Metastasis
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Small Cell Lung Carcinoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Spinal Cord Neoplasms
1
Somatostatinoma
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Temozolomide
×
90 days
×
Clear all
No trials found.